28 min listen
What Others Can Learn from COI’s Approach to Cost-Efficient Drug Development
FromThe Bio Report
ratings:
Length:
23 minutes
Released:
Jun 21, 2017
Format:
Podcast episode
Description
The high cost of drug development, the challenge of translational research, and continuing concerns with R&D efficiency has had entrepreneurs, investors, and drugmakers open to experimenting with new models of innovation. COI Pharmaceuticals, born out of a collaboration between the pharmaceutical giant GlaxoSmithKline and Avalon Ventures, is one such model that is showing traction. With management expertise, R&D infrastructure, and a collaborative environment, COI is providing promising startups with a way to accelerate their development in a capital efficient way. We spoke to Jay Lichter, president and CEO of COI Pharmaceuticals, about the COI model, the challenges of cost-effective innovation, and what can be learned from COI’s experience.
Released:
Jun 21, 2017
Format:
Podcast episode
Titles in the series (100)
How One Foundation is Getting the Biggest Bang for Its R&D Bucks: As pressure on government and corporate research budgets grow, organizations like the Multiple Myeloma Research Foundation are playing an increasingly critical role in advancing and accelerating drug development. The foundation’s efforts, including i... by The Bio Report